randomized controlled trial

A proof-of-concept, randomized controlled trial of DAR-0100A, a dopamine-1 receptor agonist, for cognitive enhancement in schizophrenia

Authors: Ragy R Girgis, Jared X Van Snellenberg, Andrew Glass, Lawrence S Kegeles, Judy L Thompson, Melanie Wall, Raymond Y Cho, Cameron S Carter, Mark Slifstein, Anissa Abi-Dargham, Jeffrey A Lieberman

Journal: Journal of Psychopharmacology

Year Published: 2016

Background: Evidence from preclinical and human studies indicates the presence of reduced dopamine-1 receptor (D1R) signaling in the cortex, where D1Rs predominate, in patients with schizophrenia (SCZ), which may contribute to their cognitive deficits. Furthermore, studies […]

The selective neurokinin 3 antagonist AZD2624 does not improve symptoms or cognition in schizophrenia: a proof-of-principle study

Authors: Robert E Litman, Mark A Smith, Dhaval G Desai, Thomas Simpson, Dennis Sweitzer, Stephen J Kanes

Journal: Journal of Clinical Psychopharmacology

Year Published: 2014

Problems with the efficacy of second-generation antipsychotics on negative symptoms and cognition have highlighted the need for further development of drugs targeting central nervous system neurotransmitter systems other than dopamine. One target in development is neurokinin […]

Back to Publications